替诺福韦酯治疗妊娠慢性乙肝患者的疗效及母婴阻断的有效性研究  

Clinical Study on the Effectiveness and Mother-to-infant Blocking Transmission by Tenofovir Disoproxil in Treatment of Patients with Chronic Hepatitis B Throughout Pregnancy

作　　者：齐丽韫[1] 赵志军[1] 刘加群[1] 

机构地区：[1]秦皇岛市第三医院肝病科,秦皇岛066000

出　　处：《中国医药导刊》2017年第2期176-177,共2页Chinese Journal of Medicinal Guide

摘　　要：目的:探索慢性乙型肝炎(乙肝)患者妊娠期服用替诺福韦酯的疗效及对母婴阻断的有效性。方法:86例早期妊娠合并HBsAg、HbeAg阳性孕妇按照用药与否分为治疗组(54例)及对照组(32例)。结果:孕早期治疗组患者ALT复常率及HBV DNA转阴率分别为无显著差异(P>0.05),在孕早期治疗组患者的ALT复常率及HBVDNA转阴率为15例(27.7%)、5例(9.25%),对照组为8例(25.0%)、0,组间比较无显著性差异(P>0.05);孕中期治疗组ALT复常率及HBVDNA转阴率为37例(68.5%)、32例(59.3%)对照组为13例(40.6%)、1例(3.1%)(P<0.05);孕晚期治疗组ALT复常率及HBVDNA转阴率为48例(88.9%)、47例(87.0%)对照组为18例(56.3%)、3例(9.3%)(P<0.05)。结论:替诺福韦不仅可治疗孕妇慢性乙肝,并可有效阻断母婴HBV垂直传播,对母婴的安全性高,副作用少。Objective：To explore antiviral efficacy and blocking of mother-to-infant transmission by administrating tenofovir disoproxil in pregnant tatients with chronic hepatitis B throughout pregnancy.Methods：86 female early pregnancy（0 - 12 weeks） patients with chronic hepatitis B were divided into two treatmeng group（n =54） and control group（n =32）.Results：Early pregnancy rate of treatment group patients ALT after often and HBV DNA overcast rate respectively,there was no significant difference（P〉0.05）,the treatment group patients in the early stages of pregnancy rate of ALT after often turn and HBVDNA rate for 15（27.7%）,5（9.25%）,the control group of 8（25.0%）,and 0,between groups was no significant difference（P〉0.05）;Mid pregnancy after treatment group ALT often rate and HBVDNA overcast rate was 37（68.5%）,32（59.3%） in the control group of 13（40.6%）,1（3.1%）（P〈0.05）;Late pregnancy after treatment group ALT often rate and HBVDNA overcast rate for 48（88.9%）,47（87.0%） of the control group of 18（56.3%）,3（9.3%）（P〈0.05）.Conclusion：Tenofovir disoproxil show distinct antiviral effect and effectively blocking the HBV mother-to-infant transmission.The treatment was relatively safe for mother and babies.

关 键 词：替诺福韦 慢性乙型肝炎 母婴传播 妊娠 

分 类 号：R714.251[医药卫生—妇产科学]